Geriatric Medicines Market
Geriatric Medicines Market Report By Therapeutic Category (Analgesic, Anti-Hypertensive, Anti-Diabetic, Anticoagulant, Anti-Depressant), By Condition (Cardiovascular Ailments, Arthritis, Diabetes, Neurological Disorders), By Distribution Channel & Regional Forecast 2021 to 2031
Analysis of Geriatric Medicines market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Geriatric Medicines Market Outlook
Fact.MR, a market research and competitive intelligence provider, states that the sales of geriatric medicines will reach US$ 768 Mn by the end of 2021. As per the report, geriatric medicines for cardiovascular ailments will account for 45% revenue until 2031. By the end of the forthcoming decade, the global market for geriatric medicines will likely surpass US$ 1.5 Bn.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Key Points Covered in Geriatric Medicines Industry Analysis
- Market estimates and forecast 2016 to 2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Geriatric Medicines Market and How to Navigate
- Recommendation on Key Winning Strategies
Geriatric Medicines Consumption Analysis 2016 to 2020 in Comparison to Future Outlook 2021 to 2031
As per Fact.MR’s report, from 2016 to 2020, the sales of geriatric medicines expanded at a CAGR of 5.5%. Continuous research is leading to production of newer medicines that are influencing the sales of geriatric medicines industry positively.
Amid the COVID-19 pandemic, growth prospects inclined massively, with prominent pharmaceutical giants collaborating to develop effective anti-COVID-19 orally and subcutaneously injectable drug candidates. Presently, over 2 billion people have been inoculated against the novel coronavirus.
Future growth prospects will majorly depend on efforts to curb the spread of infectious diseases and pandemics, as well as mitigation of the impact of surging cardiovascular ailments. Thus, due to the aforementioned factors, the sales of geriatric medicines is expected to register a CAGR of 7% from 2021 to 2031.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Increasing Geriatric Population to Broaden Prospects of Geriatric Medicines Industry?
There is a substantial uptick in the geriatric population worldwide. The World Health Organization (WHO) concludes that people over the age of 65 constitute the fastest-growing segment. By 2050, it is predicted that the global geriatric population shall reach 22%, reaching a figure of 2 billion.
This, in turn, has led to an increase in the incidences of chronic diseases such as cancer, diabetes, neurological ailments and respiratory problems. Thus, increasing geriatric population across the globe is anticipated to broaden prospects for geriatric medicines in the future.
Increasing government support for the elderly with respect to their health, safety and nursing care has also increased. Furthermore, growing prevalence of quality geriatric care management systems is set to provide traction to the market for geriatric medicines in the forecast period.
Region-wise Analysis
Health Management Initiatives Propelling Demand for Geriatric Medicines in North America?
According to Rural Health Information Hub, the U.S. consists of more than 46 million older adults. In addition, rise in lifestyle diseases like obesity, well-established healthcare infrastructure, surge in geriatric population and presence of key market players are anticipated to leverage the North American geriatric medicines market.
Moreover, various clinical studies, research projects and geriatric health management initiatives are underway in North America. Thus, projections indicate a market share of nearly two-fifths and a CAGR of 5.7% throughout the forecast period.
Is Investment in Healthcare Making Asia a Lucrative Market for Geriatric Medicines?
High economic growth and the resulting increase in disposable incomes, combined with a large population in emerging countries such as China and India along with consequent investment in healthcare infrastructure are anticipated to burgeon market prospects. In addition, growing cases of neurological conditions is spurring the demand for medicines in the region.
Thus, Asia is poised to emerge as a lucrative market for geriatric medicines by capturing over 20% of the global geriatric medicines revenue. Furthermore, the region is expected to register a CAGR of 6.7% is projected assessment period 2021 to 2031.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Why are Analgesic Geriatric Medicines Garnering Popularity?
The analgesic therapeutic segment is projected to capture a significant chunk of demand in the global market for geriatric medicines. Rising demand for painkillers for various chronic conditions like arthritis is anticipated to boost growth.
In addition, major drugs utilized for the geriatric population include Ibuprofen, Diclofenac, Ketorolac and Toradol have gained popularity due to their effectiveness. According to Fact.MR, the segment is projected to exhibit a CAGR of 6%, capturing over 2/5th market share, across the 2021 to 2031 forecast period.
Hypertension Accelerating Growth for Antihypertensive Therapeutics?
The antihypertensive therapeutics segment is projected to grow the fastest during the forecast period. Rising incidences of hypertension attributed to changing lifestyles and increased life expectancy are poised to leverage prospects for antihypertensive drugs.
Thus, the above mentioned factors are accelerating the growth of antihypertensive therapeutics. This has led to the antihypertensive therapeutics segment to register a CAGR of 6.3% during the forecast period.
Cardiovascular Ailments Treatment to Make Maximum Use of Geriatric Medicines?
According to Fact.MR’s forecast, geriatric medicines will be in most demand to treat cardiovascular ailments. A market share worth 45% has been projected for this segment across the forthcoming decade. Increasing prevalence of heart ailments is chiefly driving market growth.
Various manufacturers have launched potent cardiovascular medicines in recent years. For instance, Novartis AG published results of its Phase-III ORION 9, 10 and 11 trials for its Leqvio® (inclisiran) drug, which provides effective and sustained LDL-C reduction amongst atherosclerotic cardiovascular disease affected patients.
Competitive Landscape
Prominent geriatric medicines manufacturers are emphasizing on a wide array of expansion strategies, comprising of acquisitions, new product launches and collaborations. Some prominent developments in the geriatric medicines industry as follows:
- In August 2021, Pfizer announced that it will acquire Trillium Therapeutics, a clinical stage immune oncology company. The acquisition will work towards improvising the treatments of cancer. According to Pfizer, the deal is likely to be worth US$ 2.26 billion.
- In October 2021, Merck & Co. Inc. published preliminary results of the clinical trials for its Molnupiravir anti-COVID-19 drug. As per the findings, patients administered with this anti-viral halved chances of hospitalization amongst patients exhibiting mild or moderate symptoms. Those administered with this drug showed 100% recovery
Report Scope
| Attribute | Details |
|---|---|
| Market Size Value in 2021 | USD 768 Million |
| Market Value Forecast in 2031 | USD 1.5 Billion |
| Growth Rate | CAGR of 7% from 2021 to 2031 |
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | US$ Mn for Value & ‘000 Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania ; Middle East & Africa |
| Key Countries Covered | U.S, Canada, Brazil, Mexico, Germany, U.K, Spain, France, Italy, Russia, India, China, Japan, Australia, New Zealand, GCC, Israel, South Africa |
| Key Segments Covered | Therapeutic Category, Condition, Distribution Channel, Region |
| Key Companies Profiled | AstraZeneca; Merck & Co, Inc.; Pfizer, Inc.; Novartis AG; Bristol-Myers Squibb Company; Sanofi S.A.; GlaxoSmithKline Plc.; Eli Lilly and Company; Abbott Laboratories; Boehringer Ingelheim GmbH |
| Pricing | Available upon Request |
Key Segments Covered
-
Therapeutic Category :
- Analgesic Geriatric Medicines
- Anti-Hypertensive Geriatric Medicines
- Statin Geriatric Medicines
- Anti-Diabetic Geriatric Medicines
- Proton Pump Inhibitor Geriatric Medicines
- Anticoagulant Geriatric Medicines
- Anti-Psychotic Geriatric Medicines
- Anti-Depressant Geriatric Medicines
-
Condition :
- Geriatric Medicines for Cardiovascular Ailments
- Geriatric Medicines for Arthritis
- Geriatric Medicines for Diabetes
- Geriatric Medicines for Neurological Disorders
- Geriatric Medicines for Cancer
- Geriatric Medicines for Osteoporosis
- Geriatric Medicines for Respiratory Disorders
- Geriatric Medicines for Other Conditions
-
Distribution Channel :
- Geriatric Medicines Sales via Hospital Pharmacies
- Geriatric Medicines Sales via Retail Pharmacies
- Geriatric Medicines Sales via Online Pharmacies
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Dynamics
- 6. Global Geriatric Medicines Market Analysis, by Therapeutic Category
- 6.1. Analgesic
- 6.2. Antihypertensive
- 6.3. Statins
- 6.4. Antidiabetic
- 6.5. Proton Pump Inhibitor
- 6.6. Anticoagulant
- 6.7. Antipsychotic and Antidepressant
- 6.8. Others
- 7. Global Geriatric Medicines Market Analysis, by Condition
- 7.1. Cardiovascular
- 7.2. Arthritis
- 7.3. Diabetes
- 7.4. Neurological
- 7.5. Cancer
- 7.6. Osteoporosis
- 7.7. Respiratory
- 7.8. Others
- 8. Global Geriatric Medicines Market Analysis, by Distribution Channel
- 8.1. Hospital Pharmacies
- 8.2. Retail Pharmacies
- 8.3. Online Pharmacies
- 9. Global Geriatric Medicines Market Analysis, by Region
- 9.1. North America
- 9.2. Europe
- 9.3. Asia Pacific
- 9.4. Latin America
- 9.5. Middle East & Africa
- 10. North America Geriatric Medicines Market Analysis
- 11. Europe Geriatric Medicines Market Analysis
- 12. Asia Pacific Geriatric Medicines Market Analysis
- 13. Latin America Geriatric Medicines Market Analysis
- 14. Middle East & Africa Geriatric Medicines Market Analysis
- 15. Competition Landscape
- 15.1. Pfizer, Inc.
- 15.2. Merck & Co., Inc.
- 15.3. AstraZeneca
- 15.4. Bristol-Myers Squibb Company
- 15.5. Novartis AG
- 15.6. Sanofi S.A.
- 15.7. GlaxoSmithKline plc
- 15.8. Eli Lilly and Company
- 15.9. Abbott Laboratories
- 15.10. Boehringer Ingelheim GmbH
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 2: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 3: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Analgesic, 2016 to 2020
Table 4: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Analgesic, 2021 to 2031
Table 5: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Antihypertensive, 2016 to 2020
Table 6: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Antihypertensive, 2021 to 2031
Table 7: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Statins, 2016 to 2020
Table 8: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Statins, 2021 to 2031
Table 9: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Antidiabetic, 2016 to 2020
Table 10: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Antidiabetic, 2021 to 2031
Table 11: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Proton Pump Inhibitor, 2016 to 2020
Table 12: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Proton Pump Inhibitor, 2021 to 2031
Table 13: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Anticoagulant, 2016 to 2020
Table 14: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Anticoagulant, 2021 to 2031
Table 15: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Antipsychotic and Antidepressant, 2016 to 2020
Table 16: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Antipsychotic and Antidepressant, 2021 to 2031
Table 17: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Others, 2016 to 2020
Table 18: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Others, 2021 to 2031
Table 19: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 20: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 21: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Cardiovascular, 2016 to 2020
Table 22: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Cardiovascular, 2021 to 2031
Table 23: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Arthritis, 2016 to 2020
Table 24: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Arthritis, 2021 to 2031
Table 25: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Diabetes, 2016 to 2020
Table 26: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Diabetes, 2021 to 2031
Table 27: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Neurological, 2016 to 2020
Table 28: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Neurological, 2021 to 2031
Table 29: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Cancer, 2016 to 2020
Table 30: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Cancer, 2021 to 2031
Table 31: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Osteoporosis, 2016 to 2020
Table 32: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Osteoporosis, 2021 to 2031
Table 33: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Respiratory, 2016 to 2020
Table 34: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Respiratory, 2021 to 2031
Table 35: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Others, 2016 to 2020
Table 36: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Others, 2021 to 2031
Table 37: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Distribution Channel, 2016 to 2020
Table 38: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Distribution Channel, 2021 to 2031
Table 39: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Hospital Pharmacies, 2016 to 2020
Table 40: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Hospital Pharmacies, 2021 to 2031
Table 41: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Retail Pharmacies, 2016 to 2020
Table 42: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Retail Pharmacies, 2021 to 2031
Table 43: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Online Pharmacies, 2016 to 2020
Table 44: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Online Pharmacies, 2021 to 2031
Table 45: Global Geriatric Medicines Market Size (US$ Mn) Analysis, by Region, 2016 to 2020
Table 46: Global Geriatric Medicines Market Size (US$ Mn) Forecast, by Region, 2021 to 2031
Table 47: North America Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 48: North America Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 49: North America Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 50: North America Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 51: North America Geriatric Medicines Market Size (US$ Mn) Analysis, by Country, 2016 to 2020
Table 52: North America Geriatric Medicines Market Size (US$ Mn) Forecast, by Country, 2021 to 2031
Table 53: Europe Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 54: Europe Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 55: Europe Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 56: Europe Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 57: Europe Geriatric Medicines Market Size (US$ Mn) Analysis, by Country, 2016 to 2020
Table 58: Europe Geriatric Medicines Market Size (US$ Mn) Forecast, by Country, 2021 to 2031
Table 59: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 60: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 61: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 62: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 63: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Analysis, by Country, 2016 to 2020
Table 64: Asia Pacific Geriatric Medicines Market Size (US$ Mn) Forecast, by Country, 2021 to 2031
Table 65: Latin America Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 66: Latin America Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 67: Latin America Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 68: Latin America Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 69: Latin America Geriatric Medicines Market Size (US$ Mn) Analysis, by Country, 2016 to 2020
Table 70: Latin America Geriatric Medicines Market Size (US$ Mn) Forecast, by Country, 2021 to 2031
Table 71: MEA Geriatric Medicines Market Size (US$ Mn) Analysis, by Therapeutic Category, 2016 to 2020
Table 72: MEA Geriatric Medicines Market Size (US$ Mn) Forecast, by Therapeutic Category, 2021 to 2031
Table 73: MEA Geriatric Medicines Market Size (US$ Mn) Analysis, by Condition, 2016 to 2020
Table 74: MEA Geriatric Medicines Market Size (US$ Mn) Forecast, by Condition, 2021 to 2031
Table 75: MEA Geriatric Medicines Market Size (US$ Mn) Analysis, by Country, 2016 to 2020
Table 76: MEA Geriatric Medicines Market Size (US$ Mn) Forecast, by Country, 2021 to 2031
Table 77: U.S. Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 78: Canada Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 79: Brazil Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 80: Mexico Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 81: Argentina Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 82: Germany Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 83: France Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 84: Italy Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 85: Spain Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 86: U.K. Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 87: Benelux Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 88: Russia Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 89: China Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 90: Japan Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 91: South Korea Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 92: India Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 93: Thailand Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 94: Indonesia Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 95: Malaysia Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 96: Australia & New Zealand Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 97: GCC Countries Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 98: Egypt Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 99: South Africa Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
Table 100: Turkey Geriatric Medicines Market Size (US$ Mn), 2021 to 2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Mechanical Ventilators Market Snapshot
Figure 02: Global Mechanical Ventilators Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021 to 2031
Figure 03: Market Value Share By Product Type (2020)
Figure 04: Market Value Share By Interface (2020)
Figure 05: Market Value Share By End User (2020)
Figure 06: Market Value Share By Region (2020)
Figure 07: Global Mechanical Ventilators Market Value Share, by Product Type, 2021 and 2031
Figure 08: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2021 to 2031, by Critical Care Ventilators
Figure 09: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2021 to 2031, by Neonatal Ventilators
Figure 10: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2021 to 2031, by Neonatal Ventilators
Figure 11: Global Mechanical Ventilators Market Value Share, by Interface, 2021 and 2031
Figure 12: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2021 to 2031, by Invasive Ventilators
Figure 13: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2021 to 2031, by Noninvasive Ventilators
Figure 14: Global Mechanical Ventilators Market Value Share, by End-user, 2021 and 2031
Figure 15: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals and Clinics, 2021 to 2031
Figure 16: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgery Centres, 2021 to 2031
Figure 17: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gynecology Clinics, 2021 to 2031
Figure 18: Global Mechanical Ventilators Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021 to 2031
Figure 19: Global Mechanical Ventilators Market Value Share, by Region, 2021 and 2031
Figure 20: North America Mechanical Ventilators Market Value (US$ Mn) Forecast, 2021 to 2031
Figure 21: North America Market Attractiveness Analysis, by Country
Figure 22: North America Mechanical Ventilators Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 23: North America Mechanical Ventilators Market Value Share Analysis, by Interface, 2021 and 2031
Figure 24: North America Mechanical Ventilators Market Value Share Analysis, by End-user, 2021 and 2031
Figure 25: North America Mechanical Ventilators Market Value Share Analysis, by Country, 2021 and 2031
Figure 26: Europe Mechanical Ventilators Market Value (US$ Mn) Forecast, 2021 to 2031
Figure 27: Europe Market Attractiveness Analysis, by Country
Figure 28: Europe Mechanical Ventilators Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 29: Europe Mechanical Ventilators Market Value Share Analysis, by Interface, 2021 and 2031
Figure 30: Europe Mechanical Ventilators Market Value Share Analysis, by End-user, 2021 and 2031
Figure 31: Europe Mechanical Ventilators Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 32: Asia Pacific Mechanical Ventilators Market Value (US$ Mn) Forecast, 2021 to 2031
Figure 33: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
Figure 34: Asia Pacific Mechanical Ventilators Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 35: Asia Pacific Mechanical Ventilators Market Value Share Analysis, by Interface, 2021 and 2031
Figure 36: Asia Pacific Mechanical Ventilators Market Value Share Analysis, by End-user, 2021 and 2031
Figure 37: Asia Pacific Mechanical Ventilators Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 38: Latin America Mechanical Ventilators Market Value (US$ Mn) Forecast, 2021 to 2031
Figure 39: Latin America Market Attractiveness Analysis, by Country
Figure 40: Latin America Mechanical Ventilators Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 41: Latin America Mechanical Ventilators Market Value Share Analysis, by Interface, 2021 and 2031
Figure 42: Latin America Mechanical Ventilators Market Value Share Analysis, by End User, 2021 and 2031
Figure 43: Latin America Mechanical Ventilators Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 44: Middle East & Africa Mechanical Ventilators Market Value (US$ Mn) Forecast, 2021 to 2031
Figure 45: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
Figure 46: Middle East & Africa Mechanical Ventilators Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 47: Middle East & Africa Mechanical Ventilators Market Value Share Analysis, by Interface, 2021 and 2031
Figure 48: Middle East & Africa Mechanical Ventilators Market Value Share Analysis, by End-user, 2021 and 2031
Figure 49: Middle East & Africa Mechanical Ventilators Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 50: Teleflex Incorporated Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 51: Teleflex Incorporated R&D Expense (%), 2016 to 2020
Figure 52: Teleflex Incorporated Breakdown of Net Sales, by Region, 2020
Figure 53: Teleflex Incorporated Breakdown of Net Sales, by End Market, 2020
Figure 54 : Dragerwerk AG & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Figure 55 : Dragerwerk AG & Co. KGaA Breakdown of Net Sales, by Region, 2020
Figure 56 : Dragerwerk AG & Co. KGaA Marketing & Sales and R&D Expenses, 2016 to 2020
Figure 57: GE Healthcare Revenue (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Figure 58: GE Healthcare Breakdown of Net Sales, by Region, 2020
Figure 59: GE Healthcare Breakdown of Net Sales, by Product Segment, 2020
Figure 60: Medtronic plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 61: Medtronic plc Marketing & Sales and R&D Expenses, 2016 to 2020
Figure 62: Medtronic plc Breakdown of Net Sales, by Business Segment, 2020
Figure 63:Medtronic plc Breakdown of Net Sales, by Region, 2020
Figure 64: Koninklijke Philips N.V. Breakdown of Net Sales, by Region, 2020
Figure 65: Merck & Co., Inc. Break-up of Net Sales, by Region, 2020
Figure 66: AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2020
Figure 68: AstraZeneca Marketing & Sales and R&D Expenses, 2016 to 2020
Figure 69: Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 70: Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2016 to 2020
Figure 71: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2020
Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 73: Novartis AG Marketing & Sales and R&D Expenses, 2016 to 2020
Figure 74: Novartis AG Breakdown of Net Sales, by Business Segment, 2020
Figure 75: Novartis AG Breakdown of Net Sales, by Region, 2020
Figure 76: Sanofi S.A. Breakdown of Net Sales, by Region, 2020
Figure 77: Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 78: Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2020
Figure 79: Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2016 to 2020
Figure 80: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2016 to 2020
Figure 81: GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2016 to 2020
Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2020
Figure 83: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2020
Figure 84: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Figure 85: Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2016 to 2020
Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Region, 2020
Figure 87: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Figure 88: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2020
Figure 89: Abbott Laboratories, Breakdown of Net Sales, by Region 2020
Figure 90: Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Figure 91: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2020
Figure 92: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2020
Figure 93: Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2016 to 2020
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the geriatric medicines industry worth?
As of 2021, the market for geriatric medicines will reach US$ 768 Mn
At what rate will the geriatric medicines industry grow from 2021 to 2031?
The geriatric medicines industry is expected to surpass a CAGR of 7% from 2021 to 2031
What was last 5 years market CAGR for geriatric medicines?
From 2016 to 2020, geriatric medicines sales surged at a CAGR of 5.5%, according to Fact.MR
How much is the geriatric medicines market like to be valued by 2031?
The geriatric medicines market is expected to reach US$ 1.5 Bn by 2031
What are the growth prospects for geriatric medicines in North America?
North America is likely to surge at a CAGR of 5.7% from 2021 to 2031, with respect to geriatric medicines demand
How opportunistic is the market across Asia?
Asia will likely by the fastest growing market, registering a CAGR of 6.7% until 2031
Who are the prominent geriatric medicines market players?
AstraZeneca, Merck & Co, Inc., Pfizer, Inc., Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Abbott Laboratories and Boehringer Ingelheim GmbH are some prominent geriatric medicine market players
Which type of geriatric medicines is expected to hold the highest share for sales?
Antihypertensive therapeutic category is expected to hold the highest share for sales, expanding at over 6.3% CAGR
For which condition will geriatric medicines be most consumed?
Geriatric medicines for cardiovascular ailments will likely be most demanded, accounting for 45% revenue share
Geriatric Medicines Market